FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade

Article Link: FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade

December 13, 2017 — Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor…

Source: FDA New Drug Approvals